We're crowdfunding! Own a part of our business. Capital at Risk.
View our pitch

Stablepharma awarded £50,000 as part of UK research and innovation program

Express Pharma highlights the significant amount of H2020 funding that has helped UK Bio/Pharma companies advance their innovative technologies – Stablepharma Ltd received €50,000 to further develop its StablevaX™ technology. Full article can be found here. 

Through the Brexit deal struck between the UK and EU on 24 December 2021, the UK will be part of Horizon Europe, the EU’s next framework program for research and innovation. The UK-EU trade deal will give the UK researchers and businesses access to Horizon Europe funding on equivalent terms as EU counterparts, including eligibility to lead projects, says GlobalData.

Keshalini Sabaratnam, Pharma Analyst at GlobalData, comments, “Despite the Brexit deal to be part of Horizon Europe, the UK will be excluded from the new European Innovation Council Accelerator fund, which was specifically set up to provide equity investments to start-ups, university spin-offs, and small and medium-sized enterprises (SMEs). This blocks UK companies access to a significant pot of funding for new technology and research.”

The UK’s participation in Horizon 2020 (H2020), the 2014–2020 research and innovation framework, remains unchanged. This will allow UK firms to continue to participate and receive funding for the full duration of individual projects.

Sabaratnam adds, “A significant amount of H2020 funding has helped several UK Bio/Pharma companies advance their innovative technologies towards clinical trials. As such, the UK’s continued participation in the EU’s research framework programs, which provide access to funding, networks, and collaborations, will be instrumental in propelling further growth and innovation in the sector in the coming years and will help advance innovative technologies towards commercialisation.”

Stablepharma received €50,000 ($59,900) to further develop its StablevaX technology, which can thermally stabilise and deliver a wide range of vaccines without requiring refrigeration.

Ms Sabaratnam continues, “Stablepharma has so far identified over 90 vaccines suitable to use with the StablevaX technology.”


Photo; Gorodenkoff / Shutterstock